Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) has been given a $25.00 price target by analysts at Cantor Fitzgerald in a report released on Friday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 16.17% from the stock’s current price.
The analysts wrote, “There has been some concern that VRX’s Xifaxan could face competition from Cosmo Pharmaceuticals (Not Covered) as early as 2019. We reiterate our Overweight rating and price target of $25; we don’t see fundamental reasons for the stock’s weakness this morning.””
VRX has been the topic of several other research reports. Piper Jaffray Companies reissued a “sell” rating and issued a $12.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Friday, November 10th. Vetr raised shares of Valeant Pharmaceuticals Intl from a “buy” rating to a “strong-buy” rating and set a $19.72 price target on the stock in a research report on Tuesday, December 5th. TD Securities raised shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Tuesday, November 7th. ValuEngine raised shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. Finally, Wells Fargo & Co reaffirmed a “sell” rating on shares of Valeant Pharmaceuticals Intl in a research note on Friday, October 27th. Six research analysts have rated the stock with a sell rating, nine have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Valeant Pharmaceuticals Intl has a consensus rating of “Hold” and an average price target of $18.56.
Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.14. Valeant Pharmaceuticals Intl had a net margin of 15.35% and a return on equity of 51.56%. equities research analysts expect that Valeant Pharmaceuticals Intl will post 3.82 earnings per share for the current fiscal year.
In related news, Director John Paulson purchased 344,216 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was acquired at an average price of $14.40 per share, with a total value of $4,956,710.40. Following the purchase, the director now directly owns 94,559 shares in the company, valued at $1,361,649.60. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 5.87% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the business. Riggs Asset Managment Co. Inc. grew its stake in Valeant Pharmaceuticals Intl by 118.2% in the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock worth $119,000 after buying an additional 4,512 shares in the last quarter. Cetera Investment Advisers purchased a new position in Valeant Pharmaceuticals Intl in the 2nd quarter worth approximately $192,000. Harbour Capital Advisors LLC purchased a new position in Valeant Pharmaceuticals Intl in the 3rd quarter worth approximately $224,000. American Century Companies Inc. purchased a new position in Valeant Pharmaceuticals Intl in the 3rd quarter worth approximately $238,000. Finally, Moors & Cabot Inc. grew its stake in Valeant Pharmaceuticals Intl by 32.3% in the 2nd quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock worth $267,000 after buying an additional 3,725 shares in the last quarter. 49.45% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Valeant Pharmaceuticals Intl (VRX) Given a $25.00 Price Target at Cantor Fitzgerald” was published by American Banking and Market News and is owned by of American Banking and Market News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/19/valeant-pharmaceuticals-intl-vrx-given-a-25-00-price-target-at-cantor-fitzgerald.html.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
